Page 11 - HFA_Dateline_2017_Q2_Fall_Special_Edition

Indications (FVIII,FIX,vWD, Inh, etc) Notes
VIII Product is manufactured by Bayer; Helixate is sold and marketed by CSL Behring.
VIII
Helixate FS will no longer be manufactured after December 2017. Supply will continue
VIII to be available through early 2019.

VIII
VIII

VIII a-Results from 30 previously treated patients (PTPs) 12 to 60 years old, who received a
Indicated in adults and children with Hemophilia A single infusion of 50 IU/kg XYNTHA. b-Compared to adults, the half-life of XYNTHA
for: 1) On-demand treatment and control of bleeding is shorter in children and the clearance (based on per kg body weight) is approximately
episodes 2) Perioperative (surgical) management 40% higher in children.
of bleeding and 3) Routine prophylaxis to reduce a-Results from 30 previously treated patients (PTPs) 12 to 60 years old, who received a
the frequency of bleeding episodes. NUWIQ is single infusion of 50 IU/kg XYNTHA. b-Compared to adults, the half-life of XYNTHA
not indicated for the treatment of von Willebrand is shorter in children and the clearance (based on per kg body weight) is approximately
Disease. 40% higher in children.
VIII

VIII

VIII
VIII
VIII

Special Issue Fall 2017 | Dateline Federation 11